Earlier this week, ACADIA Pharmaceuticals reported third-quarter results showing revenue of US$278.63 million and net income of US$71.78 million, alongside a raised full-year revenue outlook and plans ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Neurological biotech Acadia Pharmaceuticals recently rolled out a rebrand as it seeks to expand further into the rare disease space. As is the case with most life sciences companies these days, AI ...

Acadia Pharmaceuticals ACAD reported third-quarter 2025 earnings of 26 cents per share (excluding a one-time tax benefit), ...

ACADIA Pharmaceuticals Inc. (($ACAD)) has held its Q3 earnings call. Read on for the main highlights of the call. ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc (ACAD) reports an 11% revenue increase, driven by strong sales of DAYBUE and NUPLAZID, while navigating challenges in market penetration and R&D expenses.

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.5, a high estimate of $39.00, and a low estimate of $28.00. Marking an increase of 2.76%, the current ...

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101 ...

Mark Schneyer, EVP at ACADIA Pharmaceuticals ACAD, reported an insider sell on September 16, according to a new SEC filing. In the Wednesday's morning session, ACADIA Pharmaceuticals's shares are ...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.